
    
      Primary Objective:

        -  To determine whether subjects with stage IV melanoma randomized to HSPPC-96 have longer
           survival than subjects randomized to physician's choice including interleukin-2 and/or
           dacarbazine/temozolomide and/or complete tumor resection.

      Secondary Objective:

        -  To determine frequency of adverse events in subjects randomized to HSPPC-96.
    
  